Active surveillance for oesophageal cancer after chemoradiotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates an active surveillance approach for patients with locally advanced oesophageal cancer who have completed neoadjuvant chemoradiotherapy. It aims to monitor the safety and effectiveness of this approach in a prospective cohort, as current evidence suggests that active surveillance may be a viable alternative to immediate surgery. The study is an extension of the SANO trial, which has shown high participation rates and a demand for tailored surgical approaches based on patient preferences. Continuous monitoring of safety and implementation will be conducted until the final results of the SANO trial are available.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Operable patients who are planned to undergo or who recently underwent neoadjuvant chemoradiotherapy according to CROSS followed by surgical resection for histologically proven oesophageal squamous cell carcinoma or adenocarcinoma of the oesophagus or oesophago-gastric junction
* Age ≥18
* Written, voluntary, informed consent.

Exclusion Criteria:

* Non-FDG-avid tumour at baseline PET-CT scan
* Initial treatment with endoscopic resection
* Patients who underwent of who are planned to undergo definitive chemoradiotherapy
* Language difficulty, dementia or altered mental status prohibiting the understanding and giving of informed consent.

Where it's running

• Erasmus University Medical Center
  Rotterdam, South Holland, Netherlands Recruiting

Study contacts

• Principal investigator: Bas Wijnhoven, Dr. — Erasmus Medical Center
• Study coordinator: Charlène vd Zijden, Drs.
• Email: c.vanderzijden@erasmusmc.nl
• Phone: +31107041223

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Exploring biomarkers for personalized treatment in esophageal cancer

  This study is testing if certain blood markers can help doctors better understand and treat patients with esophageal cancer before surgery.

  Recruiting Heinrich-Heine University, Duesseldorf · Cologne, North Rhine-Westphalia and 1 other locations · NCT04455282

• AI-based precision oncology clinical trial matching and registry

  This study is testing whether an AI tool can help match cancer patients with the right clinical trials based on their specific cancer details to see if it improves their chances of getting into trials and their overall outcomes.

  Recruiting at 68 sites Massive Bio, Inc. · Birmingham, Alabama and 67 other locations · NCT03452774

• Survey for patients with esophageal cancer and upper digestive diseases

  This study is trying to gather information from patients with esophageal cancer and other upper digestive issues to see how they are doing after treatment and improve future care.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT02530983

• Personalized Ultrafractionated Stereotactic Radiotherapy with Perioperative FLOT for GEJ and Esophageal Cancer

  This trial tests adding a personalized, ultra-fractionated radiotherapy boost (PULSAR) to standard perioperative FLOT chemotherapy for patients with esophageal or gastroesophageal junction cancer to see if it can be used safely.

  Recruiting Phase 1 University of Texas Southwestern Medical Center · Dallas, Texas · NCT07700420

• Preventing nausea and vomiting during multi-cycle chemo and immunotherapy in esophageal and lung cancer

  This study tests a combination antiemetic with dexamethasone to see if it lowers nausea and vomiting in adults with esophageal or lung cancer receiving several cycles of chemo plus immunotherapy.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07617246

• Ivonescimab plus FOLFOX for advanced HER2-negative stomach and gastroesophageal junction adenocarcinoma

  This study tests whether adding ivonescimab to standard FOLFOX chemotherapy helps people with advanced, HER2-negative stomach or gastroesophageal junction adenocarcinoma as first-line treatment.

  Recruiting at 2 sites Phase 2 Massachusetts General Hospital · Santa Monica, California and 1 other locations · NCT07070466

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.